Serotonin and depression: pathophysiological mechanism or marketing myth?

Trends in Pharmacological Sciences

Volumn 29, Issue 9, 2008, Pages 433-436

  Cowen, Philip J ^a  

^a WARNEFORD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; PROLACTIN; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN;

ARTICLE; DEPRESSION; DRUG EFFICACY; DRUG MARKETING; HUMAN; HYPOTHESIS; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROLACTIN RELEASE; PSYCHOTHERAPY; RECEPTOR DENSITY; RELAPSE; SEROTONIN BRAIN LEVEL; SEROTONIN UPTAKE; SEROTONINERGIC SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SYMPTOMATOLOGY;

DEPRESSION; HUMANS; SEROTONIN; TRYPTOPHAN;

EID: 50549084169     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2008.05.004     Document Type: Article

References (36)

1. Coppen A. The biochemistry of affective disorders. Br. J. Psychiatry 113 (1967) 1237-1264
2. Cowen P.J. A role for 5-HT in the action of antidepressant drugs. Pharmacol. Ther. 46 (1990) 43-51
3. (2005) Eli Lilly: correction and apology. BMJ 330, 211
4. Kirsch I., et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the food and drug administration. PLoS Med. 5 (2008) e45. http://medicine.plosjournals.org 10.1371/journal.pmed.0050045
5. Whittington C.J., et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 363 (2004) 1341-1345
6. Lacasse J.R., and Leo J. Serotonin and depression: A disconnect between the advertisements and the scientific literature. PLoS Med. 2 (2005) e392. http://medicine.plosjournals.org 10.1371/journal.pmed.0020392
7. Healy D. The Creation of Psychopharmacology (2002), Harvard University Press
8. Healy D., et al. Peripheral adrenoceptors and serotonin receptors in depression: changes associated with response to treatment with trazodone or amitriptyline. J. Affect. Disord. 9 (1985) 285-296
9. Yeo I.B. An address on the therapeutics of the uric acid diathesis. BMJ 1 (1888) 16-19
10. Coppen A., et al. Platelet 5 hydroxytryptamine accumulation in depressive illness. Clin. Chim. Acta 87 (1978) 165-168
11. Cowen P.J., et al. Decreased plasma tryptophan levels in major depression. J. Affect. Disord. 16 (1989) 27-31
12. Cowen P.J. Neuroendocrine markers of depression and antidepressant drug action. In: Leonard B.E., et al. (Ed). Antidepressants (2001), Birkhauser Verlag 95-107
13. Bhagwagar Z., et al. State and trait abnormalities in serotonin in major depression. Br. J. Psychiatry 180 (2002) 24-28
14. Grasby P.M. Imaging the neurochemical brain in health and disease. Clin. Med. 2 (2002) 67-73
15. 11C]WAY-100635: effects of depression and antidepressant treatment. Arch. Gen. Psychiatry 57 (2000) 174-180
16. Drevets W.C., et al. Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nucl. Med. Biol. 34 (2007) 865-877
17. 11C]WAY-100635. Mol. Psychiatry 9 (2004) 386-392
18. A receptor in panic disorder. J. Neurosci. 24 (2004) 589-591
19. 11C]MDL 100, 907. Am. J. Psychiatry 163 (2006) 1580-1587
20. 11C] DASB. Am. J. Psychiatry 164 (2007) 1858-1865
21. Laruelle M., and Abi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J. Psychopharmacol. 13 (1999) 358-371
22. 18F]MPPF binding potential in the dorsal raphe nucleus after a single oral dose of fluoxetine: a positron-emission tomography study in healthy volunteers. Biol. Psychiatry 63 (2008) 1135-1140. www.sciencedirect.com
23. Caspi A., et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301 (2003) 386-389
24. Hariri A.R., et al. A susceptibility gene for affective disorders and the response of the human amygdala. Arch. Gen. Psychiatry 62 (2005) 146-152
25. Flint J., and Muafo M.R. The endophenotype concept in psychiatric genetics. Psychol. Med. 37 (2007) 163-180
26. Willis-Owen S.A., et al. The serotonin transporter length polymorphism, neuroticism, and depression: a comprehensive assessment of association. Biol. Psychiatry 58 (2005) 451-456
27. Young S.N., et al. Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology (Berl.) 87 (1985) 173-177
28. Ruhe H.G., et al. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol. Psychiatry 12 (2007) 331-359
29. Smith K.A., et al. Relapse of depression after rapid depletion of tryptophan. Lancet 349 (1997) 915-919
30. Berman R.M., et al. Transient depressive relapse induced by catecholamine depletion: potential phenotypic vulnerability marker?. Arch. Gen. Psychiatry 56 (1999) 395-403
31. Hayward G., et al. Low-dose tryptophan depletion in recovered depressed patients induces changes in cognitive processing without depressive symptoms. Biol. Psychiatry 57 (2005) 517-524
32. Harmer C.J., et al. Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am. J. Psychiatry 161 (2004) 1256-1263
33. Bhagwagar Z., et al. Normalization of enhanced fear recognition by acute SSRI treatment in subjects with a previous history of depression. Am. J. Psychiatry 161 (2004) 166-168
34. Mössner R., et al. Consensus paper of the WFSBP task force on biological markers: biological markers in depression. World J. Biol. Psychiatry 8 (2007) 141-174
35. Mendelson S.D. The current status of the platelet 5-HT(2A) receptor in depression. J. Affect. Disord. 57 (2000) 13-24
36. Reddy P.L. CSF amine metabolites in depression. Biol. Psychiatry 31 (1992) 112-118